Evidence map›Paper›PMID 29511965›Full record

ArticleBreast cancer research and treatment2018

Exercise and weight loss interventions and miRNA expression in women with breast cancer.

Brian D Adams, Hannah Arem, Monica J Hubal, Brenda Cartmel, Fangyong Li, Maura Harrigan, Tara Sanft, Christopher J Cheng, Lajos Pusztai, Melinda L Irwin

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Brian D AdamsThe RNA Institute, University at Albany State University of New York, Albany, NY, 12222, USA.
Hannah AremDepartment of Epidemiology and Biostatistics, Milken Institute of Public Health George Washington University, Washington, DC, 20052, USA.
Monica J HubalDepartment of Exercise and Nutrition Sciences, Milken Institute of Public Health George Washington University, Washington, DC, 20052, USA.
Brenda CartmelYale School of Public Health, New Haven, CT, 06510, USA.
Fangyong LiYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, 06510, USA.
Maura HarriganYale School of Public Health, New Haven, CT, 06510, USA.
Tara SanftYale Medical Oncology, Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, 06511, USA.
Christopher J ChengDivision of Nucleic Acid Technology, Alexion Pharmaceuticals, Cheshire, CT, 06410, USA.
Lajos PusztaiYale Medical Oncology, Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, 06511, USA.
Melinda L IrwinYale School of Public Health, New Haven, CT, 06510, USA. melinda.irwin@yale.edu.
Yale University · USSmilow Cancer Hospital · USAlexion Pharmaceuticals (United States) · USApplied Physical Sciences (United States) · USGeorge Washington University · USMilken Institute · US

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Shuangge Ma · 2015 to 2026
$31.1M
A randomized trial of lifestyle guidelines on breast cancer biomarkers and treatment adherenceR01CA207753 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L, SANFT, TARA B · 2017 to 2021
$3.5M
MicroRNAs in agingR01AG033921 · NIA · YALE UNIVERSITY · PI SLACK, FRANK J. · 2009 to 2018
$3.3M
RCT of exercise on aromatase inhibitor side effects in breast cancer survivorsR01CA132931 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2009 to 2012
$2.4M
National Cancer Institute (US) R01CA132931NCATS NIH HHS UL1 TR000142NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA132931NCI NIH HHS R01 CA207753NIA NIH HHS R01 AG033921
6 · The paper itself

Abstract

purposeObesity and weight gain are associated with comorbidities including a higher risk of tumor recurrence and cancer-related deaths among breast cancer (BC) survivors; however, the underlying mechanisms linking obesity and cancer are poorly understood. Given the lack of clinically validated BC biomarkers, obesity and weight-loss studies utilize serum biomarkers as the intermediary outcomes of tumor recurrence. Studies have indicated microRNAs (miRNA)s are reliable biomarkers for cancer. We hypothesized that miRNA expression correlates with obesity and weight loss amongst BC survivors. This would yield insight into the biological pathways by which this association occurs, enabling more precise development of therapeutics. PATIENTS AND

methodsWe correlated baseline body mass index (BMI) with serum miRNA expression in 121 BC survivors enrolled in the Hormones and Physical Exercise (HOPE) trial. We then analyzed expression of the 35 most abundant miRNAs from HOPE in a six-month randomized controlled weight-loss trial (Lifestyle, Exercise, and Nutrition; LEAN) in 100 BC survivors. Ingenuity pathway analysis (IPA) software was used to identify biological pathway targets of the BMI-associated and intervention-responsive miRNAs using predictive biomarkers.

resultsPearson correlations in HOPE identified eight miRNAs associated with BMI, including miR-191-5p (r = - 0.22, p = 0.016) and miR-122-5p (r = 0.25, p = 0.0048). In the LEAN validation study, levels of miR-191-5p significantly increased during the six-month intervention (p = 0.082). Ingenuity Pathway Analysis identified "Estrogen-mediated S-phase entry" (HOPE p = 0.003; LEAN p < 0.001) and "Molecular mechanisms of cancer" (HOPE p = 0.02; LEAN p < 0.001) as the top canonical pathways that significantly correlated with BMI-associated and intervention-responsive miRNAs and contain obesity and cancer-relevant genes including the E2F family of transcription factors and CCND1, which have been implicated in sporadic BC.

conclusionWhile the association between obesity and BC recurrence and mortality has been demonstrated in the literature, mechanisms underlying the link between weight gain and cancer are unclear. Using two independent clinical trials, we identified novel miRNAs associative to BMI and weight loss that contribute to the development of cancer. Predictive modeling of miRNA targets identified multiple canonical pathways associated with cancer, highlighting potential mechanisms explaining the link between BMI and increased cancer risk.

Indexed as

AdultAgedBiomarkers, TumorBody Mass IndexBreast NeoplasmsExerciseFemaleHumansMicroRNAsMiddle AgedNeoplasm Recurrence, LocalObesityWeight LossBiomarkers, TumorMicroRNAsMIRN122 microRNA, humanMIRN191 microRNA, humanBiomarkersBreast cancerDietExerciseMicroRNAmiRNAObesityWeight loss

Identifiers

PMID29511965
PMCPMC6444907
OpenAlexW2792354551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.